6Takeshi Nakajima,Ichiro Oda,Takuji Gotoda,Hisanao Hamanaka,Takako Eguchi,Chizu Yokoi,Daizo Saito. Metachronous gastric cancers after endoscopic resection: how effective is annual endoscopic surveillance?[J] 2006,Gastric Cancer(2):93～98
7Jaffer A. Ajani,Chris Takimoto,Carlos R. Becerra,Alejandro Silva,Luis Baez,Allen Cohn,Pierre Major,Makio Kamida,Kevie Feit,Robert Jager. A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer[J] 2005,Investigational New Drugs(5):479～484
8Yukako Akatsu,Yoshiro Saikawa,Tetsuro Kubota,Masashi Yoshida,Toshiharu Furukawa,Yoshihide Otani,Koichiro Kumai,Masaki Kitajima. Clinical and pathological disappearance of peritoneal dissemination in a patient with advanced gastric cancer receiving chemotherapy with S-1 and low-dose cisplatin[J] 2004,Gastric Cancer(2):128～133
9A. Kominea,P. A. Konstantinopoulos,N. Kapranos,G. Vandoros,M. Gkermpesi,P. Andricopoulos,S. Artelaris,S. Savva,I. Varakis,G. Sotiropoulou-Bonikou,A. G. Papavassiliou. Androgen receptor (AR) expression is an independent unfavorable prognostic factor in gastric cancer[J] 2004,Journal of Cancer Research and Clinical Oncology(5):253～258
10Takashi Iwazawa,Masakatsu Kinuta,Hiroshi Yano,Shigeo Matsui,Shinji Tamagaki,Atsushi Yasue,Kazuyuki Okada,Toshiyuki Kanoh,Takeshi Tono,Yoshiaki Nakano,Shigeru Okamoto,Takushi Monden. An oral anticancer drug, TS-1, enabled a patient with advanced gastric cancer with Virchow’s metastasis to receive curative resection[J] 2002,Gastric Cancer(2):96～101
